Critical Analysis: Medical Marijuana (OTCMKTS:MJNA) and Gyre Therapeutics (NASDAQ:GYRE)

Medical Marijuana (OTCMKTS:MJNA) and Gyre Therapeutics (NASDAQ:GYRE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Profitability

This table compares Medical Marijuana and Gyre Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medical Marijuana	N/A	N/A	N/A
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

Valuation & Earnings

This table compares Medical Marijuana and Gyre Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medical Marijuana	N/A	N/A	N/A	($0.01)	-0.03
Gyre Therapeutics	$116.59 million	6.61	$5.03 million	($0.21)	-32.90

Gyre Therapeutics has higher revenue and earnings than Medical Marijuana. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Medical Marijuana, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.0% of Medical Marijuana shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Medical Marijuana and Gyre Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medical Marijuana	0	0	0	0	0.00
Gyre Therapeutics	2	0	2	0	2.00

Gyre Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 146.02%. Given Gyre Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Medical Marijuana.

Summary

Gyre Therapeutics beats Medical Marijuana on 6 of the 11 factors compared between the two stocks.

About Medical Marijuana

Medical Marijuana, Inc., an investment holding company, operates in the cannabinoid-based nutraceutical industry. It focuses on the development, sale, and distribution of hemp oil that contains naturally occurring cannabinoids, including cannabidiol (CBD) and other products containing CBD-rich hemp oil; treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products; and nonpsychoactive cannabidiol products. The company is also involved in the research and development of new therapeutic agents that are designed to reduce oxidative stress and act as immuno-modulators and neuroprotectants; dietary supplements, skin care products, and prescription-based hemp oil under the Kannaway and HempMeds brands; and proprietary testing, genetics, labeling and packaging, tracking, and production and standardization methods for the medicinal cannabinoid industry. In addition, it offers RSHO oil for the treatment of various illnesses and conditions; and plant-based, non-GMO pet products for health and wellness, play and wear, and environmentally-friendly supplies. Medical Marijuana, Inc. was incorporated in 2005 and is based in San Diego, California.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.